Showing results (2281-2290 of 6,794) with videos related to

Sort By:
Pageof 680
Clinical Therapeutics|September 12, 2019
Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site AdministrationLindsay M Avery, Iris H Chen, Sergio Reyes, et al.
Clinical Therapeutics|August 14, 2019
Recurrent Thrombosis With Direct Oral Anticoagulants in Antiphospholipid Syndrome: A Systematic Literature Review and Meta-analysisJorge Sanchez-Redondo, Gerard Espinosa, David Varillas Delgado, et al.
Clinical Therapeutics|January 1, 1985
Prospective, randomized comparison of the efficacy and safety of netilmicin-clindamycin and tobramycin-clindamycin in the treatment of serious systemic infectionsS Kahalley, J Chandler, J Hawkins, et al.
Clinical Therapeutics|October 8, 2019
Insights Into Patients' Experience With Type 1 Diabetes: Exit Interviews From Phase III Studies of SotagliflozinClaire Ervin, Vijay N Joish, Emily Evans, et al.
Clinical Therapeutics|October 7, 2022
Characteristics of Real-world Commercially Insured Patients With Treatment-resistant Depression Initiated on Esketamine Nasal Spray or Conventional Therapies in the United StatesSwapna Karkare, Maryia Zhdanava, Dominic Pilon, et al.
Clinical Therapeutics|March 15, 2011
Efficacy and tolerability of besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days in the treatment of bacterial conjunctivitis: a multicenter, randomized, double-masked, vehicle-controlled, parallel-group study in adults and childrenBruce E Silverstein, Catherine Allaire, Kirk M Bateman, et al.
Clinical Therapeutics|March 15, 2011
Concurrent control of blood glucose, body mass, and blood pressure in patients with type 2 diabetes: an analysis of data from electronic medical recordsCarrie McAdam-Marx, Jonathan Bouchard, Mark Aagren, et al.
Clinical Therapeutics|March 15, 2011
Medication adherence affects treatment modifications in patients with type 2 diabetesJaco Voorham, Flora M Haaijer-Ruskamp, Bruce H R Wolffenbuttel, et al.
Clinical Therapeutics|March 15, 2011
Bioavailability of three rufinamide oral suspensions compared with the marketed 400-mg tablet formulation: results from a randomized-sequence, open-label, four-period, four-sequence crossover study in healthy subjectsDavid John Critchley, Jagadeesh Aluri, Peter Boyd, et al.
Clinical Therapeutics|June 4, 2011
Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German settingChristian Asseburg, Martin Frank, Claus-Henning Köhne, et al.
Pageof 680